Clinical Trial Update: A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies [Phase 2]

View source ↗

Summary

A Phase 2 follow-up trial to assess resistance to ABT-072 in subjects with hepatitis C who previously received ABT-072; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-072

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Hepatitis C Virus Infection | Phase 2 | Status: COMPLETED